ALAB Shares Drop Again as 15 Analysts Suggest Buying the Dip

TLDR

• On March 30, ALAB fell 7.2% to close at $104.41, reaching an intraday low of $102.20 with trading volume far below the average
• Currently, the stock is 60% below its 52-week high of $262.90 and trades beneath both its 50-day ($138.30) and 200-day ($162.90) moving averages
• Q4 revenue rose 91.8% year-over-year, and earnings per share (EPS) exceeded expectations by $0.07; the company’s guidance for Q1 2026 is EPS of $0.53 to $0.54
• Analysts stay optimistic, with a consensus “Moderate Buy” rating and an average price target of $202.22—almost twice the current share price
• Over the past three months, insiders sold approximately 384,292 shares valued at $48.7 million, yet they still hold 12.5% of the company

(SeaPRwire) –   Astera Labs (ALAB) declined 7.2% on March 30, ending the day at $104.41 after hitting an intraday low of $102.20. The previous session’s closing price was $112.47.

Astera Labs, Inc. Common Stock, ALAB

Trading volume was significantly light. Between 566,620 and 1.7 million shares were traded (depending on the session data), which is well below the daily average of about 5.1 to 5.2 million shares. Low volume during a downward move can sometimes indicate a lack of strong selling conviction rather than a widespread sell-off.

This decline pushes ALAB further into a tough period. The stock is now 60% below its 52-week high of $262.90, though it’s still over 120% above its 52-week low of $47.13.

Both moving averages are trending downward. The 50-day moving average is at $138.30 and the 200-day at $162.90—both well above Monday’s closing price—confirming the stock has been in a downtrend for a while.

Strong Fundamentals, Weak Chart

The company’s fundamentals paint a contrasting picture. In Q4, Astera Labs reported revenue of $270.58 million, a 91.8% year-over-year increase and higher than the analyst consensus of $249.46 million. EPS was $0.58, which beat the expected $0.51 by $0.07. Net margin was 25.70% and return on equity was 16.12%.

For Q1 2026, the company provided EPS guidance of $0.53 to $0.54. Analysts forecast an average full-year EPS of $0.34.

Wall Street hasn’t lost faith. Among the 23 analysts covering the stock, 15 have a Buy rating, six have a Hold, and only one has a Sell. The consensus rating is either “Moderate Buy” or “Outperform,” depending on the data source. Average price targets range from $202 to $204, suggesting potential upside of about 95–97% from current prices. Individual targets go as high as $250 to $275.

Insiders Have Been Selling

The analysts’ optimism isn’t shared by the executive team, at least not lately. Insiders sold roughly 384,292 shares over the past three months, valued at around $48.7 million.

General Counsel Philip Mazzara sold 10,000 shares on March 2 at $117.47, cutting his stake by 7.24%. COO Sanjay Gajendra sold 94,971 shares in February at an average price of $123.81, reducing his position by 5.84%.

Even with these sales, insiders together still own 12.5% of the company. Institutional investors hold around 60.5% of the float, and several have been increasing their positions lately. Royal Bank of Canada expanded its stake by 167.3% in Q1. AQR Capital Management raised its position by 213.4%. Empowered Funds grew its holdings by 917.3%.

With a market capitalization of $16.79 billion and a P/E ratio of 80.39, the stock has a growth premium. Its beta of 1.75 indicates it tends to move significantly in either direction.

As of the March 30 close, ALAB was trading between $104.01 and $104.41, about 60% below its all-time high and well below all major analyst price targets.